Invention Grant
US09175320B2 Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof
有权
（R）-2-（7-4-环戊基-3-（三氟甲基）苄氧基）-1,2,3,4-四氢环戊二烯并[B]吲哚-3-基）乙酸及其盐的制备方法
![Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof](/docs/US/2015-11-03/US09175320B2/abs.jpg.600x600.jpg)
- Patent Title: Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof
- Patent Title (中): （R）-2-（7-4-环戊基-3-（三氟甲基）苄氧基）-1,2,3,4-四氢环戊二烯并[B]吲哚-3-基）乙酸及其盐的制备方法
-
Application No.: US14464251Application Date: 2014-08-20
-
Publication No.: US09175320B2Publication Date: 2015-11-03
- Inventor: Antonio Garrido Montalban , Daniel J. Buzard , John A. DeMattei , Tawfik Gharbaoui , Stephen R. Johannsen , Ashwin M. Krishnan , Young Mi Kuhlman , You-An Ma , Michael John Martinelli , Suzanne Michiko Sato , Dipanjan Sengupta
- Applicant: ARENA PHARMACEUTICALS, INC.
- Applicant Address: US CA San Diego
- Assignee: Arena Pharmaceuticals, Inc.
- Current Assignee: Arena Pharmaceuticals, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Fish & Richardson P.C.
- Agent Lyle W. Spruce
- Main IPC: C07D209/80
- IPC: C07D209/80 ; C07D209/94 ; C12P17/10 ; C07C17/278 ; C07D209/88 ; C07D295/155
![Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof](/abs-image/US/2015/11/03/US09175320B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to processes and intermediates useful in the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of Formula (Ia) and salts thereof, an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).
Public/Granted literature
Information query
